“Fentanyl is like the boogeyman, it’s ubiquitous, it’s everywhere. It’ll creep in your mask, and there’s nothing you can do.” — Jon Zibbell, PhD, of RTI International in North Carolina, on a CDC video used to warn of fentanyl threat to police that may mislead officers about their risk of exposure and overdose.
“Otherwise, these who are using fallacious arguments like Nuremberg 2.0 are going to win.” — Timothy Caulfield, ML, of the University of Alberta in Canada, on getting medical institutions to protect members who are speaking out about scientific truth.
“We’re learning to fly the plane, while we’re flying the plane.” — Jeffrey Fine, MD, of NYU Langone Hospital, on programs treating patients with long COVID.
“If I invite you to my party, and you’re like, ‘Oh, hey, I’ll be there,’ but you come virtually, and then like 10 other people come in person, who am I going to favor?” — Mahad Minhas, MD, a radiology resident weighing virtual options for residency interviews against the high cost of traveling in-person.
“I think my biggest disappointment is the use by FDA of unequal standards for different medications.” — David Boulware, MD, of the University of Minnesota, after the agency rejected an emergency use authorization application for selective serotonin reuptake inhibitor fluvoxamine to treat COVID-19.
“It remains unknown which guidance predominates in clinical practice.” — Mohammed Ali, MD, MSc, MBA, of Emory University Rollins School of Public Health in Atlanta, comparing the the U.S. Preventive Services Task Force and American Diabetes Association’s updated diabetes screening guidelines.